{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T16:15:35Z","timestamp":1775924135469,"version":"3.50.1"},"publisher-location":"Singapore","reference-count":121,"publisher":"Springer Singapore","isbn-type":[{"value":"9789811602665","type":"print"},{"value":"9789811602672","type":"electronic"}],"license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021]]},"DOI":"10.1007\/978-981-16-0267-2_5","type":"book-chapter","created":{"date-parts":[[2021,7,13]],"date-time":"2021-07-13T20:02:36Z","timestamp":1626206556000},"page":"115-138","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Moving Fast Toward Hepatitis B Virus Elimination"],"prefix":"10.1007","author":[{"given":"Leda","family":"Bassit","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suzane Kioko","family":"Ono","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raymond F.","family":"Schinazi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,7,14]]},"reference":[{"key":"5_CR1","doi-asserted-by":"crossref","unstructured":"Razavi H (2020) Global epidemiology of viral hepatitis. Gastroenterol Clin North Am 49:179\u2013189","DOI":"10.1016\/j.gtc.2020.01.001"},{"key":"5_CR2","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1007\/s00535-020-01680-0","volume":"55","author":"RS De Fraga","year":"2020","unstructured":"De Fraga RS, Van Vaisberg V, Mendes LCA et al (2020) Adverse events of nucleos(t)ide analogues for chronic hepatitis B: a systematic review. J Gastroenterol 55:496\u2013514","journal-title":"J Gastroenterol"},{"key":"5_CR3","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","volume":"67","author":"Easl","year":"2017","unstructured":"Easl (2017) EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection. J Hepatol 67:370\u2013398","journal-title":"J Hepatol"},{"key":"5_CR4","doi-asserted-by":"publisher","first-page":"8078","DOI":"10.1038\/s41598-019-44604-6","volume":"9","author":"X Zhang","year":"2019","unstructured":"Zhang X, Chen X, Wei M et al (2019) Potential resistant mutations within HBV reverse transcriptase sequences in nucleos(t)ide analogues-experienced patients with hepatitis B virus infection. Sci Rep 9:8078","journal-title":"Sci Rep"},{"key":"5_CR5","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1093\/cid\/cix129","volume":"64","author":"TM Block","year":"2017","unstructured":"Block TM, Locarnini S, Mcmahon BJ et al (2017) Use of current and new endpoints in the evaluation of experimental hepatitis B therapeutics. Clin Infect Dis 64:1283\u20131288","journal-title":"Clin Infect Dis"},{"key":"5_CR6","unstructured":"Anonymous (2020) Drug watch - compound in development for chronic hepatitis B. Hepatitis B Foundation.\u00a0https:\/\/www.hepb.org\/treatment-and-management\/drug-watch\/"},{"key":"5_CR7","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1002\/jmv.24270","volume":"87","author":"YY Zhang","year":"2015","unstructured":"Zhang YY, Hu KQ (2015) Rethinking the pathogenesis of hepatitis B virus (HBV) infection. J Med Virol 87:1989\u20131999","journal-title":"J Med Virol"},{"key":"5_CR8","doi-asserted-by":"publisher","first-page":"S60","DOI":"10.1016\/j.jhep.2016.01.028","volume":"64","author":"MK Maini","year":"2016","unstructured":"Maini MK, Gehring AJ (2016) The role of innate immunity in the immunopathology and treatment of HBV infection. J Hepatol 64:S60\u2013S70","journal-title":"J Hepatol"},{"key":"5_CR9","doi-asserted-by":"publisher","first-page":"497","DOI":"10.5009\/gnl17233","volume":"12","author":"A Bertoletti","year":"2018","unstructured":"Bertoletti A, Le Bert N (2018) Immunotherapy for chronic hepatitis B virus infection. Gut Liver 12:497\u2013507","journal-title":"Gut Liver"},{"key":"5_CR10","doi-asserted-by":"publisher","first-page":"6457","DOI":"10.3748\/wjg.v20.i21.6457","volume":"20","author":"J Lin","year":"2014","unstructured":"Lin J, Wu JF, Zhang Q et al (2014) Virus-related liver cirrhosis: molecular basis and therapeutic options. World J Gastroenterol 20:6457\u20136469","journal-title":"World J Gastroenterol"},{"key":"5_CR11","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.jhep.2019.11.003","volume":"72","author":"M Cornberg","year":"2020","unstructured":"Cornberg M, Lok AS, Terrault NA et al (2020) Guidance for design and endpoints of clinical trials in chronic hepatitis B - report from the 2019 EASL-AASLD HBV treatment endpoints conference. J Hepatol 72:539\u2013557","journal-title":"J Hepatol"},{"key":"5_CR12","doi-asserted-by":"publisher","first-page":"3165","DOI":"10.3748\/wjg.v22.i11.3165","volume":"22","author":"A Madej\u00f3n","year":"2016","unstructured":"Madej\u00f3n A, Romero M, Hern\u00e1ndez \u00c1 et al (2016) Hepatitis B and D viruses replication interference: influence of hepatitis B genotype. World J Gastroenterol 22:3165\u20133174","journal-title":"World J Gastroenterol"},{"key":"5_CR13","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.virol.2018.04.015","volume":"519","author":"V Sozzi","year":"2018","unstructured":"Sozzi V, Shen F, Chen J et al (2018) In vitro studies identify a low replication phenotype for hepatitis B virus genotype H generally associated with occult HBV and less severe liver disease. Virology 519:190\u2013196","journal-title":"Virology"},{"key":"5_CR14","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1038\/s41573-019-0057-9","volume":"19","author":"GC Fanning","year":"2020","unstructured":"Fanning GC, Zoulim F, Hou J et al (2020) Therapeutic strategies for hepatitis B virus infection: towards a cure. Nat Rev Drug Discov 19:291","journal-title":"Nat Rev Drug Discov"},{"key":"5_CR15","doi-asserted-by":"publisher","first-page":"3895","DOI":"10.1007\/s00018-018-2892-y","volume":"75","author":"C Eller","year":"2018","unstructured":"Eller C, Heydmann L, Colpitts CC et al (2018) The functional role of sodium taurocholate cotransporting polypeptide NTCP in the life cycle of hepatitis B, C and D viruses. Cell Mol Life Sci 75:3895\u20133905","journal-title":"Cell Mol Life Sci"},{"key":"5_CR16","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1021\/acsinfecdis.8b00081","volume":"5","author":"J Hu","year":"2019","unstructured":"Hu J, Cheng J, Tang L et al (2019) Virological basis for the cure of chronic hepatitis B. ACS Infect Dis 5:659\u2013674","journal-title":"ACS Infect Dis"},{"key":"5_CR17","doi-asserted-by":"publisher","first-page":"1972","DOI":"10.1136\/gutjnl-2015-309809","volume":"64","author":"M Nassal","year":"2015","unstructured":"Nassal M (2015) HBV cccDNA: viral persistence reservoir and key obstacle for a cure of chronic hepatitis B. Gut 64:1972\u20131984","journal-title":"Gut"},{"key":"5_CR18","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1126\/science.1243462","volume":"343","author":"J Lucifora","year":"2014","unstructured":"Lucifora J, Xia Y, Reisinger F et al (2014) Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA. Science 343:1221\u20131228","journal-title":"Science"},{"key":"5_CR19","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1002\/hep.21299","volume":"44","author":"A Laras","year":"2006","unstructured":"Laras A, Koskinas J, Dimou E et al (2006) Intrahepatic levels and replicative activity of covalently closed circular hepatitis B virus DNA in chronically infected patients. Hepatology 44:694\u2013702","journal-title":"Hepatology"},{"key":"5_CR20","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01117-18","volume":"92","author":"B Qu","year":"2018","unstructured":"Qu B, Ni Y, Lempp FA et al (2018) T5 exonuclease hydrolysis of hepatitis B virus replicative intermediates allows reliable quantification and fast drug efficacy testing of covalently closed circular DNA by PCR. J Virol 92:e01117","journal-title":"J Virol"},{"key":"5_CR21","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1172\/JCI11100","volume":"107","author":"SK Ono","year":"2001","unstructured":"Ono SK, Kato N, Shiratori Y et al (2001) The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance. J Clin Invest 107:449\u2013455","journal-title":"J Clin Invest"},{"key":"5_CR22","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1177\/135965350400900311","volume":"9","author":"O Lada","year":"2004","unstructured":"Lada O, Benhamou Y, Cahour A et al (2004) In vitro susceptibility of lamivudine-resistant hepatitis B virus to adefovir and tenofovir. Antivir Ther 9:353\u2013363","journal-title":"Antivir Ther"},{"key":"5_CR23","unstructured":"Idenix Pharmaceuticals I (2006) NDA 22-011 TYZEKA\u2122. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2006\/022011lbl.pdf"},{"key":"5_CR24","unstructured":"Gilead (2016) NDA 208464. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2016\/208464Orig1s000MedR.pdf"},{"key":"5_CR25","doi-asserted-by":"publisher","first-page":"797","DOI":"10.2147\/TCRM.S1965","volume":"4","author":"HL Tillmann","year":"2008","unstructured":"Tillmann HL (2008) The treatment of chronic hepatitis B: Focus on adefovir-like antivirals. Ther Clin Risk Manag 4:797\u2013802","journal-title":"Ther Clin Risk Manag"},{"key":"5_CR26","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1111\/jvh.12418","volume":"23","author":"V Kim","year":"2016","unstructured":"Kim V, Abreu RM, Nakagawa DM et al (2016) Pegylated interferon alfa for chronic hepatitis B: systematic review and meta-analysis. J Viral Hepat 23:154\u2013169","journal-title":"J Viral Hepat"},{"issue":"Suppl 1","key":"5_CR27","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1111\/liv.13656","volume":"38","author":"RF Schinazi","year":"2018","unstructured":"Schinazi RF, Ehteshami M, Bassit L et al (2018) Towards HBV curative therapies. Liver Int 38(Suppl 1):102\u2013114","journal-title":"Liver Int"},{"key":"5_CR28","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/S0140-6736(05)17701-0","volume":"365","author":"HL Janssen","year":"2005","unstructured":"Janssen HL, Van Zonneveld M, Senturk H et al (2005) Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 365:123\u2013129","journal-title":"Lancet"},{"key":"5_CR29","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.3851\/IMP1458","volume":"14","author":"R Moucari","year":"2009","unstructured":"Moucari R, Martinot-Peignoux M, Mackiewicz V et al (2009) Influence of genotype on hepatitis B surface antigen kinetics in hepatitis B e antigen-negative patients treated with pegylated interferon-alpha2a. Antivir Ther 14:1183\u20131188","journal-title":"Antivir Ther"},{"key":"5_CR30","doi-asserted-by":"publisher","first-page":"567","DOI":"10.3851\/IMP3338","volume":"24","author":"RM Abreu","year":"2019","unstructured":"Abreu RM, Bassit LC, Tao S et al (2019) Long-term virological and adherence outcomes to antiviral treatment in a 4-year cohort chronic HBV study. Antivir Ther 24:567\u2013579","journal-title":"Antivir Ther"},{"key":"5_CR31","doi-asserted-by":"publisher","first-page":"93","DOI":"10.3350\/cmh.2019.1002","volume":"25","author":"Kasl","year":"2019","unstructured":"Kasl (2019) KASL clinical practice guidelines for management of chronic hepatitis B. Clin Mol Hepatol 25:93\u2013159","journal-title":"Clin Mol Hepatol"},{"key":"5_CR32","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.3346\/jkms.2017.32.11.1857","volume":"32","author":"SH Park","year":"2017","unstructured":"Park SH, Park KS, Kim NH et al (2017) Clevudine induced mitochondrial myopathy. J Korean Med Sci 32:1857\u20131860","journal-title":"J Korean Med Sci"},{"key":"5_CR33","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1111\/jvh.12807","volume":"25","author":"PH Naylor","year":"2018","unstructured":"Naylor PH, Mutchnick MG (2018) Immunotherapy for hepatitis B in the direct acting antiviral era: reevaluating the thymosin \u03b11 efficacy trials in the light of a combination therapy approach. J Viral Hepat 25:4\u20139","journal-title":"J Viral Hepat"},{"key":"5_CR34","first-page":"348","volume":"13","author":"MG Peters","year":"2017","unstructured":"Peters MG, Locarnini S (2017) New direct-acting antiviral agents and immunomodulators for hepatitis B virus infection. Gastroenterol Hepatol 13:348\u2013356","journal-title":"Gastroenterol Hepatol"},{"issue":"Suppl 1","key":"5_CR35","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/liv.14364","volume":"40","author":"MG Martinez","year":"2020","unstructured":"Martinez MG, Villeret F, Testoni B et al (2020) Can we cure hepatitis B virus with novel direct-acting antivirals? Liver Int 40(Suppl 1):27\u201334","journal-title":"Liver Int"},{"key":"5_CR36","volume":"64","author":"N Zhao","year":"2020","unstructured":"Zhao N, Jia B, Zhao H et al (2020) A first-in-human trial of GLS4, a novel inhibitor of hepatitis B virus capsid assembly, following single- and multiple-ascending-oral-dose studies with or without ritonavir in healthy adult volunteers. Antimicrob Agents Chemother 64:e01686","journal-title":"Antimicrob Agents Chemother"},{"key":"5_CR37","first-page":"152","volume":"5","author":"MF Yuen","year":"2020","unstructured":"Yuen MF, Agarwal K, Gane EJ et al (2020) Safety, pharmacokinetics, and antiviral effects of ABI-H0731, a hepatitis B virus core inhibitor: a randomised, placebo-controlled phase 1 trial. Gastroenterol Hepatol 5:152\u2013166","journal-title":"Gastroenterol Hepatol"},{"key":"5_CR38","doi-asserted-by":"publisher","first-page":"1497A","DOI":"10.1002\/hep.30995","volume":"70","author":"MF Yuen","year":"2019","unstructured":"Yuen MF, Agarwal K, Gane EJ et al (2019) The second-generation hepatitis B virus (HBV) core inhibitor (CI) ABI-H2158 is associated with potent antiviral activity in a 14-day monotherapy study in HBeAg-positive patients with chronic hepatitis B (CHB). Hepatology 70:1497A\u20131498A","journal-title":"Hepatology"},{"key":"5_CR39","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1111\/jvh.13351","volume":"27","author":"T Verbinnen","year":"2020","unstructured":"Verbinnen T, Hodari M, Talloen W et al (2020) Virology analysis of chronic hepatitis B virus\u2013infected patients treated for 28 days with JNJ-56136379 monotherapy. J Viral Hepat 27:1127\u20131137","journal-title":"J Viral Hepat"},{"key":"5_CR40","doi-asserted-by":"publisher","first-page":"e491","DOI":"10.1016\/S0618-8278(19)30964-8","volume":"70","author":"E Gane","year":"2019","unstructured":"Gane E, Yuen MF, Bo Q et al (2019) RO7049389, a core protein allosteric modulator, demonstrates robust decline in HBV DNA and HBV RNA in chronic HBV infected patients. J Hepatol 70:e491","journal-title":"J Hepatol"},{"key":"5_CR41","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/S0618-8278(19)30936-3","volume":"70","author":"M Vaine","year":"2019","unstructured":"Vaine M, Dellisola V, Clugston S et al (2019) EDP-514, a novel HBV core inhibitor with potent antiviral activity both in vitro and in vivo. J Hepatol 70:474\u2013475","journal-title":"J Hepatol"},{"key":"5_CR42","doi-asserted-by":"publisher","first-page":"e48","DOI":"10.1016\/S0618-8278(19)30085-4","volume":"70","author":"Q Huang","year":"2019","unstructured":"Huang Q, Haydar S, Zhou Y et al (2019) Preclinical profile of HBV core protein inhibitor, ABI-H3733, a potent inhibitor of cccDNA generation in HBV infected cells. J Hepatol 70:e48","journal-title":"J Hepatol"},{"key":"5_CR43","volume":"64","author":"F Amblard","year":"2020","unstructured":"Amblard F, Boucle S, Bassit L et al (2020) Novel hepatitis B virus capsid assembly modulator induces potent antiviral responses in vitro and in humanized mice. Antimicrob Agents Chemother 64:e01701","journal-title":"Antimicrob Agents Chemother"},{"key":"5_CR44","doi-asserted-by":"publisher","first-page":"S16","DOI":"10.1016\/S0168-8278(18)30251-4","volume":"68","author":"L Bassit","year":"2018","unstructured":"Bassit L, Cox B, Ono SK et al (2018) Novel and potent HBV capsid modulator reduces HBeAg and cccDNA in core site directed T109I mutant in HepNTCP cells. J Hepatol 68:S16\u2013S17","journal-title":"J Hepatol"},{"key":"5_CR45","doi-asserted-by":"publisher","first-page":"e457","DOI":"10.1016\/S0618-8278(19)30902-8","volume":"70","author":"L Bassit","year":"2019","unstructured":"Bassit L, Verma K, Ono SK et al (2019) Novel HBV capsid assembly modulator inhibits pregenomic RNA encapsidation by accelerating capsid assembly kinetics and disrupting core protein dephosphorylation. J Hepatol 70:e457","journal-title":"J Hepatol"},{"key":"5_CR46","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1016\/j.tetlet.2017.01.006","volume":"58","author":"O Sari","year":"2017","unstructured":"Sari O, Bassit L, Gavegnano C et al (2017) Synthesis and antiviral evaluation of 2',2',3',3'-tetrafluoro nucleoside analogs. Tetrahedron Lett 58:642\u2013644","journal-title":"Tetrahedron Lett"},{"key":"5_CR47","first-page":"437A","volume":"70","author":"Y Debing","year":"2019","unstructured":"Debing Y, Jekle A, Vendeville S et al (2019) Preclinical assessment of a novel CAPSID assembly modulator, ALG-001075, demonstrates best-in-class in vitro potency and in vivo antiviral efficacy. Hepatology 70:437A","journal-title":"Hepatology"},{"key":"5_CR48","doi-asserted-by":"crossref","unstructured":"Yan H, Zhong G, Xu G et al (2012) Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus. Elife 1:e00049","DOI":"10.7554\/eLife.00049"},{"key":"5_CR49","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1111\/apt.15581","volume":"51","author":"EJ Smolders","year":"2020","unstructured":"Smolders EJ, Burger DM, Feld JJ et al (2020) Clinical pharmacology of current and investigational hepatitis B virus therapies. Aliment Pharmacol Ther 51:231\u2013243","journal-title":"Aliment Pharmacol Ther"},{"key":"5_CR50","doi-asserted-by":"publisher","first-page":"e81","DOI":"10.1016\/S0618-8278(19)30141-0","volume":"2019","author":"H Wedemeyer","year":"2019","unstructured":"Wedemeyer H, Sch\u00f6neweis K, Bogomolov P et al (2019) Final results of a multicenter, open-label phase 2 clinical trial (MYR203) to assess safety and efficacy of myrcludex B in with PEG-interferon Alpha 2a in patients with chronic HBV\/HDV co-infection. J Hepatol 2019:e81","journal-title":"J Hepatol"},{"key":"5_CR51","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/j.jhepr.2019.07.006","volume":"1","author":"JM Donkers","year":"2019","unstructured":"Donkers JM, Appelman MD, Graaf SFJ (2019) Mechanistic insights into the inhibition of NTCP by myrcludex B. JHEP Rep 1:278\u2013285","journal-title":"JHEP Rep"},{"key":"5_CR52","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1038\/35053110","volume":"409","author":"E Bernstein","year":"2001","unstructured":"Bernstein E, Caudy AA, Hammond SM et al (2001) Role for a bidentate ribonuclease in the initiation step of RNA interference. Nature 409:363\u2013366","journal-title":"Nature"},{"key":"5_CR53","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.yexmp.2014.06.006","volume":"97","author":"N Thongthae","year":"2014","unstructured":"Thongthae N, Payungporn S, Poovorawan Y et al (2014) A rational study for identification of highly effective siRNAs against hepatitis B virus. Exp Mol Pathol 97:120\u2013127","journal-title":"Exp Mol Pathol"},{"key":"5_CR54","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1038\/s41573-019-0017-4","volume":"18","author":"RL Setten","year":"2019","unstructured":"Setten RL, Rossi JJ, Han S-P (2019) The current state and future directions of RNAi-based therapeutics. Nat Rev Drug Discov 18:421\u2013446","journal-title":"Nat Rev Drug Discov"},{"key":"5_CR55","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/S1525-0016(03)00244-2","volume":"8","author":"H Giladi","year":"2003","unstructured":"Giladi H, Ketzinel-Gilad M, Rivkin L et al (2003) Small interfering RNA inhibits hepatitis B virus replication in mice. Mol Ther 8:769\u2013776","journal-title":"Mol Ther"},{"key":"5_CR56","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1007\/s12013-014-9847-1","volume":"69","author":"G Li","year":"2014","unstructured":"Li G, Jiang G, Lu J et al (2014) Inhibition of hepatitis B virus cccDNA by siRNA in transgenic mice. Cell Biochem Biophys 69:649\u2013654","journal-title":"Cell Biochem Biophys"},{"key":"5_CR57","unstructured":"Collier WH (2020) Arbutus announces positive preliminary phase 1a\/1b clinical trial results for AB-729, a proprietary GalNAc delivered RNAi compound in development for people living with chronic hepatitis B. In: GlobeNewswire, https:\/\/www.globenewswire.com\/news-release\/2020\/03\/26\/2007290\/0\/en\/Arbutus-Announces-Positive-Preliminary-Phase-1a-1b-Clinical-Trial-Results-for-AB-729-a-Proprietary-GalNAc-Delivered-RNAi-Compound-in-Development-for-People-Living-with-Chronic-Hepa.html"},{"key":"5_CR58","doi-asserted-by":"publisher","first-page":"S50","DOI":"10.1016\/S0168-8278(20)30647-4","volume":"73","author":"E Gane","year":"2020","unstructured":"Gane E, Lim Y-S, Tangkijvanich P et al (2020) Preliminary safety and antiviral activity of VIR-2218, an X-targeting HBV RNAi therapeutic, in chronic hepatitis B patients. J Hepatol 73:S50\u2013S51","journal-title":"J Hepatol"},{"key":"5_CR59","doi-asserted-by":"publisher","first-page":"S20","DOI":"10.1016\/S0168-8278(20)30597-3","volume":"73","author":"E Gane","year":"2020","unstructured":"Gane E, Locarnini S, Lim TH et al (2020) Short-term treatment with RNA interference therapy, JNJ-3989, results in sustained hepatitis B surface antigen suppression in patients with chronic hepatitis B receiving nucleos(t)ide analogue treatment. J Hepatol 73:S20","journal-title":"J Hepatol"},{"key":"5_CR60","doi-asserted-by":"crossref","unstructured":"Vaillant A (2016) Nucleic acid polymers: broad spectrum antiviral activity, antiviral mechanisms and optimization for the treatment of hepatitis B and hepatitis D infection. Antiviral Res 133:32\u201340","DOI":"10.1016\/j.antiviral.2016.07.004"},{"key":"5_CR61","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1021\/acsinfecdis.8b00156","volume":"5","author":"A Vaillant","year":"2019","unstructured":"Vaillant A (2019) REP 2139: antiviral mechanisms and applications in achieving functional control of HBV and HDV infection. ACS Infect Dis 5:675\u2013687","journal-title":"ACS Infect Dis"},{"key":"5_CR62","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0156667","volume":"11","author":"M Al-Mahtab","year":"2016","unstructured":"Al-Mahtab M, Bazinet M, Vaillant A (2016) Safety and efficacy of nucleic acid polymers in monotherapy and combined with immunotherapy in treatment-naive Bangladeshi patients with HBeAg+ chronic hepatitis B infection. PLoS One 11:e0156667","journal-title":"PLoS One"},{"key":"5_CR63","doi-asserted-by":"publisher","first-page":"2180","DOI":"10.1053\/j.gastro.2020.02.058","volume":"158","author":"M Bazinet","year":"2020","unstructured":"Bazinet M, P\u00e2ntea V, Placinta G et al (2020) Safety and efficacy of 48 weeks REP 2139 or REP 2165,tenofovir disoproxil, and pegylated interferon alfa-2a in patients with chronic HBV infection na\u00efve to nucleos(t)ide therapy. Gastroenterology 158:2180\u20132194","journal-title":"Gastroenterology"},{"key":"5_CR64","first-page":"70","volume":"430A","author":"J Hong","year":"2019","unstructured":"Hong J, Pandey R, Rajwanshi VK et al (2019) S-antigen traffic-inhibiting oligonucleotide polymers (STOPS) can effectively inhibit hepatitis B surface antigen (HBsAg) secretion from hepatitis B virus (HBV) cell lines. Hepatology 430A:70","journal-title":"Hepatology"},{"key":"5_CR65","doi-asserted-by":"publisher","first-page":"S868","DOI":"10.1016\/S0168-8278(20)32178-4","volume":"2020","author":"H Tan","year":"2020","unstructured":"Tan H, Hong J, Hyunsoon K et al (2020) Combination drug interactions of hepatitis B virus (HBV) S-antigen transport - inhibiting oligonucleotide polymers in vitro. J Hepatol 2020:S868","journal-title":"J Hepatol"},{"key":"5_CR66","unstructured":"Jobe A (2020) Aligos therapeutics doses first subject in phase 1 proof of concept study of oligonucleotide drug candidate ALG-010133. In: GlobeNewswire, https:\/\/www.globenewswire.com\/news-release\/2020\/08\/18\/2080093\/0\/en\/Aligos-Therapeutics-Doses-First-Subject-in-Phase-1-Proof-of-Concept-Study-of-Oligonucleotide-Drug-Candidate-ALG-010133.html"},{"key":"5_CR67","doi-asserted-by":"crossref","unstructured":"Squires KE, Mayers DL, Bluemling GR et al (2020) ATI-2173, a novel liver-targeted non-chain terminating nucleotide for HBV cure regimens. Antimicrob Agents Chemother 64:e00836-20","DOI":"10.1128\/AAC.00836-20"},{"key":"5_CR68","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1002\/cpdd.670","volume":"8","author":"K Han","year":"2019","unstructured":"Han K, Cremer J, Elston R et al (2019) A randomized, double-blind, placebo-controlled, first-time-in-human study to assess the safety, tolerability, and pharmacokinetics of single and multiple ascending doses of GSK3389404 in healthy subjects. Clin Pharmacol Drug Dev 8:790\u2013801","journal-title":"Clin Pharmacol Drug Dev"},{"key":"5_CR69","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1002\/cpdd.670","volume":"8","author":"K Han","year":"2019","unstructured":"Han K, Cremer J, Elston R et al (2019) A randomized, double-blind, placebo-controlled, first-time-in-human study to assess the safety, tolerability, and pharmacokinetics of single and multiple ascending doses of GSK3389404 in healthy subjects. Clin Pharmacol Drug Dev 8:790\u2013801","journal-title":"Clin Pharmacol Drug Dev"},{"key":"5_CR70","first-page":"S66","volume":"14","author":"H Kelong","year":"2020","unstructured":"Kelong H, Hiroshi I, Robert E et al (2020) Pharmacokinetics of GSK3389404, an antisense oligonucleotide (ASO), is similar in subjects with chronic hepatitis B (CHB) across Asia-Pacific region. Hepatol Int 14:S66","journal-title":"Hepatol Int"},{"key":"5_CR71","doi-asserted-by":"publisher","first-page":"433A","DOI":"10.1016\/S0618-8278(19)30851-5","volume":"70","author":"MF Yuen","year":"2019","unstructured":"Yuen MF, Heo J, Kumada H et al (2019) Results after 12 weeks treatment of multiple doses of GSK3389404 in chronic hepatitis B (CHB) subjects on stable nucleos(t)ide therapy in a phase 2a double-blind, placebo-controlled study. Hepatology 70:433A\u2013434A","journal-title":"Hepatology"},{"key":"5_CR72","first-page":"S72","volume":"14","author":"S Feng","year":"2020","unstructured":"Feng S, Cheung TT, Luk AOY et al (2020) Liver targeted single stranded (SSO) oligonucleotide RO7062931 is safe and well tolerated in Chinese healthy volunteers (HVs) with similar pharmacokinetic profile to non-Chinese HVs. Hepatol Int 14:S72","journal-title":"Hepatol Int"},{"key":"5_CR73","first-page":"436A","volume":"70","author":"EJ Gane","year":"2019","unstructured":"Gane EJ, Wat C, Das S et al (2019) Interim results of a phase 1 study of RO7062931, a novel liver-targeted single-stranded oligonucleotide (SSO) with locked nucleic acid (LNA) that targets HBV transcripts. Hepatology 70:436A","journal-title":"Hepatology"},{"key":"5_CR74","doi-asserted-by":"publisher","first-page":"S51","DOI":"10.1016\/S0168-8278(20)30648-6","volume":"2020","author":"M-F Yuen","year":"2020","unstructured":"Yuen M-F, Gane E, Kim DJ et al (2020) RO7062931 antisense oligonucleotide phase 1 study demonstrates target engagement in patients with chronic hepatitis B on established nucleos(t)ide therapy. J Hepatol 2020:S51","journal-title":"J Hepatol"},{"key":"5_CR75","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1021\/acsinfecdis.8b00045","volume":"5","author":"JE Tavis","year":"2019","unstructured":"Tavis JE, Zoidis G, Meyers MJ et al (2019) Chemical approaches to inhibiting the hepatitis B virus ribonuclease H. ACS Infect Dis 5:655\u2013658","journal-title":"ACS Infect Dis"},{"key":"5_CR76","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.antiviral.2017.04.012","volume":"143","author":"TC Edwards","year":"2017","unstructured":"Edwards TC, Lomonosova E, Patel JA et al (2017) Inhibition of hepatitis B virus replication by N-hydroxyisoquinolinediones and related polyoxygenated heterocycles. Antiviral Res 143:205\u2013217","journal-title":"Antiviral Res"},{"key":"5_CR77","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.antiviral.2019.02.005","volume":"164","author":"TC Edwards","year":"2019","unstructured":"Edwards TC, Mani N, Dorsey B et al (2019) Inhibition of HBV replication by N-hydroxyisoquinolinedione and N-hydroxypyridinedione ribonuclease H inhibitors. Antiviral Res 164:70\u201380","journal-title":"Antiviral Res"},{"key":"5_CR78","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1080\/14728222.2019.1619697","volume":"23","author":"TC Edwards","year":"2019","unstructured":"Edwards TC, Ponzar NL, Tavis JE (2019) Shedding light on RNaseH: a promising target for hepatitis B virus (HBV). Expert Opin Ther Targets 23:559\u2013563","journal-title":"Expert Opin Ther Targets"},{"key":"5_CR79","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2020.104777","volume":"177","author":"Q Li","year":"2020","unstructured":"Li Q, Lomonosova E, Donlin MJ et al (2020) Amide-containing \u03b1-hydroxytropolones as inhibitors of hepatitis B virus replication. Antiviral Res 177:104777","journal-title":"Antiviral Res"},{"key":"5_CR80","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.antiviral.2017.06.014","volume":"144","author":"E Lomonosova","year":"2017","unstructured":"Lomonosova E, Daw J, Garimallaprabhakaran AK et al (2017) Efficacy and cytotoxicity in cell culture of novel \u03b1-hydroxytropolone inhibitors of hepatitis B virus ribonuclease H. Antiviral Res 144:164\u2013172","journal-title":"Antiviral Res"},{"key":"5_CR81","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/978-1-4939-6700-1_14","volume":"1540","author":"E Lomonosova","year":"2017","unstructured":"Lomonosova E, Tavis JE (2017) In vitro enzymatic and cell culture-based assays for measuring activity of HBV RNaseH inhibitors. Methods Mol Biol 1540:179\u2013192","journal-title":"Methods Mol Biol"},{"key":"5_CR82","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.antiviral.2017.11.008","volume":"149","author":"KR Long","year":"2018","unstructured":"Long KR, Lomonosova E, Li Q et al (2018) Efficacy of hepatitis B virus ribonuclease H inhibitors, a new class of replication antagonists. Antivir Res 149:41\u201347","journal-title":"Antivir Res"},{"key":"5_CR83","doi-asserted-by":"publisher","first-page":"2754","DOI":"10.3390\/ijms20112754","volume":"20","author":"C Boni","year":"2019","unstructured":"Boni C, Barili V, Acerbi G et al (2019) HBV immune-therapy: from molecular mechanisms to clinical applications. Int J Mol Sci 20:2754","journal-title":"Int J Mol Sci"},{"key":"5_CR84","doi-asserted-by":"publisher","first-page":"589A","DOI":"10.1016\/S0618-8278(19)31179-X","volume":"70","author":"Y Hiasa","year":"2019","unstructured":"Hiasa Y, Yoshida O, Guillen GE et al (2019) The HB vaccine containing HBS and HBC antigen (NASVAC) can effectively induce anti-HBS antibody in non-responders to the prophylactic vaccine. Hepatology 70:589A\u2013590A","journal-title":"Hepatology"},{"key":"5_CR85","volume-title":"Globe newswire","author":"W Brown","year":"2020","unstructured":"Brown W (2020) Altimmune announces IND clearance for a phase 2 trial of HepTcell\u2122 immunotherapeutic for the treatment of chronic hepatitis B. In: Altimmune (ed) Globe newswire. Altimmune, Gaithersburg"},{"key":"5_CR86","doi-asserted-by":"publisher","first-page":"e50","DOI":"10.1016\/S0618-8278(19)30090-8","volume":"70","author":"YS Lim","year":"2019","unstructured":"Lim YS, Mutimer D, Heo J et al (2019) A phase 1b evaluation of HepTcell HBV-specific immunotherapy in NUC-controlled, eAg negative chronic HBV infection. J Hepatol 70:e50\u2013e51","journal-title":"J Hepatol"},{"key":"5_CR87","unstructured":"Daniela P (2018) AIC649 Innate activation with inactivated parapoxviruses for HBV therapy. In: International HBV Cure Meeting. Toronto"},{"key":"5_CR88","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1111\/liv.12530","volume":"35","author":"SK Yoon","year":"2015","unstructured":"Yoon SK, Seo YB, Im SJ et al (2015) Safety and immunogenicity of therapeutic DNA vaccine with antiviral drug in chronic HBV patients and its immunogenicity in mice. Liver Int 35:805\u2013815","journal-title":"Liver Int"},{"key":"5_CR89","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1080\/21645515.2019.1651141","volume":"16","author":"F Zoulim","year":"2020","unstructured":"Zoulim F, Fournier C, Habersetzer F et al (2020) Safety and immunogenicity of the therapeutic vaccine TG1050 in chronic hepatitis B patients: a phase 1b placebo-controlled trial. Hum Vaccin Immunother 16:388\u2013399","journal-title":"Hum Vaccin Immunother"},{"key":"5_CR90","unstructured":"McNally RT (2018) GeoVax and CaroGen to collaborate on development of therapeutic hepatitis B vaccine. https:\/\/www.geovax.com\/news\/geovax-and-carogen-to-collaborate-on-development-of-therapeutic-hepatitis-b-vaccine"},{"key":"5_CR91","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1080\/21645515.2019.1689081","volume":"16","author":"R George","year":"2020","unstructured":"George R, Ma A, Motyka B et al (2020) A dendritic cell-targeted chimeric hepatitis B virus immunotherapeutic vaccine induces both cellular and humoral immune responses in vivo. Hum Vaccin Immunother 16:779\u2013792","journal-title":"Hum Vaccin Immunother"},{"key":"5_CR92","doi-asserted-by":"publisher","first-page":"e485","DOI":"10.1016\/S0618-8278(19)30954-5","volume":"70","author":"J Su","year":"2019","unstructured":"Su J, Kosinska A, Brunner L et al (2019) Exploring TH1\/TH2 adjuvants to improve the efficacy of the therapeutic vaccination against chronic hepatitis B. J Hepatol 70:e485\u2013e486","journal-title":"J Hepatol"},{"key":"5_CR93","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.isci.2019.10.040","volume":"21","author":"TO Yarovinsky","year":"2019","unstructured":"Yarovinsky TO, Mason SW, Menon M et al (2019) Virus-like vesicles expressing multiple antigens for immunotherapy of chronic hepatitis B. iScience 21:391\u2013402","journal-title":"iScience"},{"key":"5_CR94","unstructured":"Tg (2018) Hookipa and Gilead ink US$400m deal. In: European Biotechnology - life science and industry magazine.\u00a0https:\/\/european-biotechnology.com\/up-to-date\/latest-news\/news\/hookipa-and-gilead-ink-us400m-deal.html"},{"key":"5_CR95","unstructured":"Vaccines V (2019) VBI Vaccines and Brii Biosciences initiate phase 1b\/2a study of BRII-179 (VBI-2601) in patients with chronic hepatitis B infection. https:\/\/www.vbivaccines.com\/wire\/vbi-and-brii-initiate-phase-1b-2a-study-of-brii-179-in-chronic-hbv\/"},{"key":"5_CR96","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2020.112238","volume":"193","author":"C Patinote","year":"2020","unstructured":"Patinote C, Karroum NB, Moarbess G et al (2020) Agonist and antagonist ligands of toll-like receptors 7 and 8: ingenious tools for therapeutic purposes. Eur J Med Chem 193:112238","journal-title":"Eur J Med Chem"},{"key":"5_CR97","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1002\/hep.31255","volume":"73","author":"S Daffis","year":"2020","unstructured":"Daffis S, Balsitis S, Chamberlain J et al (2020) Toll-like receptor 8 agonist GS-9688 induces sustained efficacy in the woodchuck model of chronic hepatitis B. Hepatology 73:53\u201367","journal-title":"Hepatology"},{"key":"5_CR98","doi-asserted-by":"crossref","unstructured":"Mackman RL, Mish M, Chin G et al (2020) Discovery of GS-9688 (Selgantolimod) as a potent and selective oral toll-like receptor 8 agonist for the treatment of chronic hepatitis B. J Med Chem 63:10188\u201310203","DOI":"10.1021\/acs.jmedchem.0c00100"},{"key":"5_CR99","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1111\/cts.12791","volume":"13","author":"A Luk","year":"2020","unstructured":"Luk A, Jiang Q, Glavini K et al (2020) A single and multiple ascending dose study of toll-like receptor 7 agonist (RO7020531) in Chinese healthy volunteers. Clin Transl Sci 13:985\u2013993","journal-title":"Clin Transl Sci"},{"key":"5_CR100","first-page":"428A","volume":"70","author":"J Blaising","year":"2019","unstructured":"Blaising J, Yu Y, Zhou X et al (2019) Combination treatment of liver-targeted HBV locked nucleic acid antisense oligonucleotide and tlr7 agonist RO7020531 leads to prolonged off-treatment antiviral effect in the AAV-HBV mouse model. Hepatology 70:428A\u2013429A","journal-title":"Hepatology"},{"key":"5_CR101","doi-asserted-by":"publisher","first-page":"5803","DOI":"10.1073\/pnas.1502400112","volume":"112","author":"G Ebert","year":"2015","unstructured":"Ebert G, Allison C, Preston S et al (2015) Eliminating hepatitis B by antagonizing cellular inhibitors of apoptosis. Proc Natl Acad Sci U S A 112:5803\u20135808","journal-title":"Proc Natl Acad Sci U S A"},{"key":"5_CR102","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.bcp.2018.04.020","volume":"154","author":"W Pan","year":"2018","unstructured":"Pan W, Luo Q, Yan X et al (2018) A novel SMAC mimetic APG-1387 exhibits dual antitumor effect on HBV-positive hepatocellular carcinoma with high expression of cIAP2 by inducing apoptosis and enhancing innate anti-tumor immunity. Biochem Pharmacol 154:127\u2013135","journal-title":"Biochem Pharmacol"},{"key":"5_CR103","doi-asserted-by":"publisher","first-page":"51","DOI":"10.3390\/pharmaceutics9040051","volume":"9","author":"DJ Trepanier","year":"2017","unstructured":"Trepanier DJ, Ure DR, Foster RT (2017) In vitro phase I metabolism of CRV431, a novel oral drug candidate for chronic hepatitis B. Pharmaceutics 9:51","journal-title":"Pharmaceutics"},{"key":"5_CR104","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0217433","volume":"14","author":"P Gallay","year":"2019","unstructured":"Gallay P, Ure D, Bobardt M et al (2019) The cyclophilin inhibitor CRV431 inhibits liver HBV DNA and HBsAg in transgenic mice. PLoS ONE 14:e0217433","journal-title":"PLoS ONE"},{"key":"5_CR105","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.3390\/molecules24071349","volume":"24","author":"C Lee","year":"2019","unstructured":"Lee C (2019) CRISPR\/Cas9-based antiviral strategy: current status and the potential challenge. Molecules 24:1349","journal-title":"Molecules"},{"key":"5_CR106","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.antiviral.2015.03.015","volume":"118","author":"C Dong","year":"2015","unstructured":"Dong C, Qu L, Wang H et al (2015) Targeting hepatitis B virus cccDNA by CRISPR\/Cas9 nuclease efficiently inhibits viral replication. Antiviral Res 118:110\u2013117","journal-title":"Antiviral Res"},{"key":"5_CR107","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.antiviral.2018.02.011","volume":"152","author":"Y Liu","year":"2018","unstructured":"Liu Y, Zhao M, Gong M et al (2018) Inhibition of hepatitis B virus replication via HBV DNA cleavage by Cas9 from Staphylococcus aureus. Antiviral Res 152:58\u201367","journal-title":"Antiviral Res"},{"key":"5_CR108","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/j.virusres.2017.06.010","volume":"244","author":"H-C Yang","year":"2018","unstructured":"Yang H-C, Chen P-J (2018) The potential and challenges of CRISPR-Cas in eradication of hepatitis B virus covalently closed circular DNA. Virus Res 244:304\u2013310","journal-title":"Virus Res"},{"key":"5_CR109","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.antiviral.2015.10.004","volume":"123","author":"EM Kennedy","year":"2015","unstructured":"Kennedy EM, Kornepati AV, Cullen BR (2015) Targeting hepatitis B virus cccDNA using CRISPR\/Cas9. Antiviral Res 123:188\u2013192","journal-title":"Antiviral Res"},{"key":"5_CR110","first-page":"480","volume":"20","author":"YC Yang","year":"2020","unstructured":"Yang YC, Chen YH, Kao JH et al (2020) Permanent inactivation of HBV genomes by CRISPR\/Cas9-mediated non-cleavage base editing. Mol Ther 20:480\u2013490","journal-title":"Mol Ther"},{"key":"5_CR111","unstructured":"Excision (2020) Technology - a novel approach to CRISPR. https:\/\/www.excision.bio\/technology"},{"key":"5_CR112","unstructured":"Haskins B (2020) Precision biosciences, Gilead sciences pull plug on potential $445M deal. WRAL TechWire. https:\/\/www.wraltechwire.com\/2020\/07\/07\/precision-biosciences-gilead-sciences-pull-plug-on-potential-445m-deal\/"},{"key":"5_CR113","unstructured":"Biosciences P (2020) ARCUS genome editing. https:\/\/precisionbiosciences.com\/our-approach\/arcus-genome-editing\/"},{"key":"5_CR114","first-page":"S48","volume":"13","author":"HW Lee","year":"2019","unstructured":"Lee HW, Park JY, Hong T et al (2019) A prospective, open-label, dose-escalation, single-center, phase 1 study for Lenvervimab (GC1102), a new and safe human monoclonal antibody drug for chronic hepatitis B patients. Hepatol Int 13:S48","journal-title":"Hepatol Int"},{"key":"5_CR115","doi-asserted-by":"publisher","first-page":"3146","DOI":"10.1096\/fj.201500134","volume":"30","author":"P Radreau","year":"2016","unstructured":"Radreau P, Porcherot M, Rami\u00e8re C et al (2016) Reciprocal regulation of farnesoid X receptor \u03b1 activity and hepatitis B virus replication in differentiated HepaRG cells and primary human hepatocytes. FASEB J 30:3146\u20133154","journal-title":"FASEB J"},{"issue":"suppl 1","key":"5_CR116","first-page":"60A","volume":"70","author":"R Darteil","year":"2019","unstructured":"Darteil R, Joly S, Radreau P et al (2019) In vitro characterization of EYP001 a novel, potent and selective FXR agonist entering phase 2 clinical trials in chronic hepatitis B. Hepatology 70(suppl 1):60A","journal-title":"Hepatology"},{"key":"5_CR117","first-page":"441A","volume":"70","author":"C Monteiro","year":"2019","unstructured":"Monteiro C, Bruezi\u00e8re L, Laheux S et al (2019) An in-silico disease model for the development of FXR agonist EYP001 as a therapy for HBV infection. Hepatology 70:441A\u2013442A","journal-title":"Hepatology"},{"key":"5_CR118","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.3389\/fimmu.2020.01037","volume":"11","author":"B Li","year":"2020","unstructured":"Li B, Yan C, Zhu J et al (2020) Anti-PD-1\/PD-L1 blockade immunotherapy employed in treating hepatitis B virus infection-related advanced hepatocellular carcinoma: a literature review. Front Immunol 11:1037\u20131037","journal-title":"Front Immunol"},{"key":"5_CR119","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1002\/cld.735","volume":"12","author":"MG Ghany","year":"2018","unstructured":"Ghany MG, Block TM (2018) Disease pathways and mechanisms of potential drug targets. Clin Liver Dis 12:12\u201318","journal-title":"Clin Liver Dis"},{"key":"5_CR120","unstructured":"LionTCR (2019) TCR T cell.\u00a0https:\/\/www.liontcr.com\/technology"},{"key":"5_CR121","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1002\/hep.31240","volume":"73","author":"Q Huang","year":"2020","unstructured":"Huang Q, Zhou B, Cai D et al (2020) Rapid turnover of HBV cccDNA indicated by monitoring emergence and reversion of signature-mutation in treated chronic hepatitis B patients. Hepatology 73:41\u201352","journal-title":"Hepatology"}],"container-title":["Advances in Experimental Medicine and Biology","Antiviral Drug Discovery and Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-981-16-0267-2_5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T01:24:49Z","timestamp":1672795489000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-981-16-0267-2_5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"ISBN":["9789811602665","9789811602672"],"references-count":121,"URL":"https:\/\/doi.org\/10.1007\/978-981-16-0267-2_5","relation":{},"ISSN":["0065-2598","2214-8019"],"issn-type":[{"value":"0065-2598","type":"print"},{"value":"2214-8019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021]]},"assertion":[{"value":"14 July 2021","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}